

Pancreatic Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/PEEC807D2404EN.html>

Date: June 2021

Pages: 60

Price: US\$ 3,000.00 (Single User License)

ID: PEEC807D2404EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Pancreatic Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pancreatic Cancer Understanding

Pancreatic Cancer: Overview

Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. Pancreatic tumors are either exocrine or neuroendocrine (endocrine) tumors. This is based on the type of cell they start in. Knowing the type of tumor is important because each type acts differently and responds to different treatments. About 93% of pancreatic cancers are exocrine tumors. The most common type of pancreatic cancer is adenocarcinoma. About 7% of pancreatic tumors are neuroendocrine tumors (pancreatic NETs or PNETs), also called islet cell tumors. They often grow slower than exocrine tumors. A pancreatic tumor can only be seen on an imaging study such as a computed tomography (CT) scan, magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS). Pancreatic cancer treatment depends on the

stage of the disease and the patient's general health.

'Pancreatic Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pancreatic Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Pancreatic Cancer.

Pancreatic Cancer Emerging Drugs Chapters

This segment of the Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pancreatic Cancer Emerging Drugs

CPI-613 (devimistat): Rafael Pharmaceuticals

Rafael's first-in-class clinical lead compound, CPI-613® (devimistat), targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. It is currently in Phase 3 in first line Pancreatic Cancer and Relapsed/Refractory AML. Additional clinical programs are also currently underway across multiple indications as a single agent, as well as in combination with standard drug therapy. The EMA has granted orphan drug designation to CPI-613® for

Pancreatic Cancer and AML. CPI-613® has IP protection and regulatory exclusivity out to 2028 and potentially beyond.

Masitinib: AB Science

Masitinib, AB Science main compound, is a selective tyrosine kinase inhibitor which is currently developed in three therapeutic areas: neurology, inflammatory diseases and oncology. As of today, masitinib is mainly developed in the following indications: amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer disease, mastocytosis, severe asthma, prostate cancer and pancreatic cancer. Masitinib pipeline is well advanced with promising phase 3 data in Amyotrophic Lateral Sclerosis (ALS), indolent severe systemic mastocytosis and severe asthma.

EndoTAG-1: Syncore Biotechnology

EndoTAG-1 (SB05) is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.

Acalabrutinib: Acerta Pharma

Acalabrutinib (ACP-196) is a highly selective, Bruton's tyrosine kinase (BTK) inhibitor developed to minimize off-target activity with minimal effects on TEC, EGFR, or ITK signaling. Acalabrutinib (ACP 196) is an orally administered, second generation, agammaglobulinaemia tyrosine kinase inhibitor. Currently, it is in phase 2 stage of development for the treatment of pancreatic cancer.

SM-88 (racemetyrosine): Tyme Technologies

SM-88 (racemetyrosine) is an orally administered cancer metabolism-based therapy

that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. Oral SM-88 has demonstrated meaningful clinical benefit and well tolerated safety profile, in metastatic cancer patients across 15 different types of solid tumors and hematologic cancers. Currently, it is in phase 3 stage of development for the treatment of pancreatic cancer.

Pamrevlumab: FibroGen

Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of locally advanced unresectable pancreatic cancer (LAPC), and in Phase 2 clinical development for the treatment of Duchenne muscular dystrophy (DMD). The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD. Pamrevlumab has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with IPF and LAPC.

Further product details are provided in the report..

Pancreatic Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pancreatic Cancer

There are approx. 100+ key companies which are developing the therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, FibroGen.

Phases

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pancreatic Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Cancer drugs.

Pancreatic Cancer Report Insights

Pancreatic Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Pancreatic Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pancreatic Cancer drugs?

How many Pancreatic Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Pancreatic Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Rafael Pharmaceuticals

AB Science

Syncore Biotechnology

Acerta Pharma

Tyme Technologies

FibroGen

Marker Therapeutics

Bristol-Myers Squibb

Helix BioPharma

Golden Biotechnology Corporation

NOXXON Pharma

Takara Bio

ARMO BioSciences

Rise Biopharmaceuticals

NanoCarrier

BeyondBio

Rexahn Pharmaceuticals, Inc.

Wuhan Binhui Biotechnology Co., Ltd.

Everfront Biotech Co., Ltd.

XBiotech, Inc.

Jiangsu Hengrui Medicine Co.

Asclepius Technology Company Group

Ability Pharmaceuticals

Lokon Pharma AB

Immunitor

Sumitomo Dainippon Pharma Oncology

Berg, LLC

BioXcel Therapeutics

Sunshine Lake Pharma

4D Pharma PLC

CrystalGenomics

Salspera

BioNTech SE

Rgene Corporation

Pharmexa

TESARO

Cend Therapeutics

AbbVie

Galera Therapeutics, Inc.

Genentech

NGM Biopharmaceuticals, Inc

Carsgen Therapeutics, Ltd.

Ascentage Pharma Group Inc.

Panbela Therapeutics, Inc.

Sorrento Therapeutics

Silenseed Ltd

Takeda Oncology

Scandion Oncology

NanOlogy, LLC

Celldex Therapeutics Inc

BioLineRx

BerGenBio ASA

Key Products

CPI-613 (devimistat)

Masitinib

EndoTAG-1

Acalabrutinib

SM-88 (racemetyrosine)

Pamrevlumab

Zelenoleucel

Nivolumab

L-DOS47

Antroquinonol

Olaptesed pegol

TBI-1401

Pegilodecakin

RP72

NC-6004

BEY1107

RX-3117

OH2 injection

EF-009

XB2001

SHR-1701

BiCAR-NK

ABTL0812

delolimogene mupadenorepvec

V3-P

Napabucasin

BPM31510

Talabostat Mesylate

Z650

SHR 3162

MRx0518

CG200745

Salmonella-IL2

MVT-5873

BLEX 404

GV1001

Niraparib

CEND-1

ABBV-927

GC4711

Atezolizumab

MVT-2163

NGM120

CT041

APG-1387

SBP-101

Anti CEA CAR T cell therapy

siG12D-LODER

TAK-931

SCO-101

NanoPa

CDX-301

BL-8040

BGB324

Contents

Introduction

Executive Summary

Pancreatic Cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Pancreatic Cancer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Pancreatic Cancer companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Pancreatic Cancer Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Pamrevlumab: FibroGen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

Acalabrutinib: Acerta Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)

Comparative Analysis

RP72: Rise Biopharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Pancreatic Cancer Key Companies

Pancreatic Cancer Key Products

Pancreatic Cancer- Unmet Needs

Pancreatic Cancer- Market Drivers and Barriers

Pancreatic Cancer- Future Perspectives and Conclusion

Pancreatic Cancer Analyst Views

Pancreatic Cancer Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Pancreatic Cancer
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Pancreatic Cancer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Pancreatic Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PEEC807D2404EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PEEC807D2404EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970